Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Sep 1987
Clinical Trial Controlled Clinical TrialAmikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma.
We report the excellent therapeutic response obtained with amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of 15 patients with actinomycotic mycetoma who had a poor response to the traditional pharmacologic agents and/or in whom important organs such as lungs, spinal cord, and bone were involved. We evaluated the results by clinical, radiologic, and laboratory tests. No important side effects were detected during or after the therapy.